Santhera Pharmaceuticals Holding AG (XSWX:SANN) Moat Score: 3/10 (As of Jul. 03, 2026)


XSWX:SANN Santhera Pharmaceuticals Holding AG XSWX:SANN
39 GF Score
Price CHF15.20
GF Value CHF23.24
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG Moat Score?

Santhera Pharmaceuticals Holding AG XSWX:SANN -0.26% 39 Moat Score is 3 as of Jul. 03, 2026. GuruFocus rates XSWX:SANN with a GF Score™ of 39/100 and a GF Value™ of CHF23.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,399 Biotechnology companies, Santhera Pharmaceuticals Holding AG ranks better than 75.48% on this metric.

Santhera Pharmaceuticals Holding AG has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Santhera Pharmaceuticals Holding AG has No Moat: Santhera Pharmaceuticals faces challenges with limited market share and weak brand strength. While it may have some intellectual property, the competitive pharmaceutical landscape and regulatory hurdles diminish its competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Santhera Pharmaceuticals Holding AG might have No Moat - Very weak/transient advantages.

Santhera Pharmaceuticals Holding AG  (XSWX:SANN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Santhera Pharmaceuticals Holding AG Moat Score Related Terms

XSWX:SANN vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santhera Pharmaceuticals Holding AG Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Moat Score distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Moat Score falls into.


XSWX:SANN
39GF Score
Santhera Pharmaceuticals Holding AG XSWX:SANN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Santhera Pharmaceuticals Holding AG (XSWX:SANN) has a Moat Score of 3 as of Jul. 03, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #343 out of 1399 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Santhera Pharmaceuticals Holding AG's Moat Score too high?
Santhera Pharmaceuticals Holding AG's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Santhera Pharmaceuticals Holding AG's value of 3 is 50% above this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #343 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #343 out of 1399 companies for Moat Score. This places Santhera Pharmaceuticals Holding AG in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Santhera Pharmaceuticals Holding AG's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (XSWX:SANN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF23.24, compared to a current price of CHF15.20 — trading 34.6% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (XSWX:SANN), the current Moat Score is 3 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santhera Pharmaceuticals Holding AG (XSWX:SANN) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of CHF15.20 is trading 34.6% below its estimated GF Value™ of CHF23.24. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Possible Value Trap.

Key valuation signals for XSWX:SANN:

  • Moat Score: 3
  • GF Value™: CHF23.24 vs. price of CHF15.20 (34.6% below fair value)
  • GF Score™: 39/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1399)

No single metric tells the full story. See the XSWX:SANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for XSWX:SANN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF15.20
Price
CHF23.24
GF Value